Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 809

1.

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E.

Breast Cancer Res Treat. 2019 May 27. doi: 10.1007/s10549-019-05284-y. [Epub ahead of print]

PMID:
31134488
2.

Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.

Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Pennacchioli E, Cocorocchio E, Ferrucci PF, De Marinis F, Gelber RD, Goldhirsch A.

J Natl Cancer Inst. 2019 May 20. pii: djz094. doi: 10.1093/jnci/djz094. [Epub ahead of print]

PMID:
31106827
3.

Recent advances in triple negative breast cancer: the immunotherapy era.

Marra A, Viale G, Curigliano G.

BMC Med. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5. Review.

4.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G.

Breast Cancer Res Treat. 2019 May 7. doi: 10.1007/s10549-018-05112-9. [Epub ahead of print]

PMID:
31065870
5.

Analytical validation of a standardized scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG).

Histopathology. 2019 Apr 24. doi: 10.1111/his.13880. [Epub ahead of print]

PMID:
31017314
6.

Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series.

Leonardi MC, Corrao G, Frassoni S, Vingiani A, Dicuonzo S, Lazzeroni M, Fodor C, Morra A, Gerardi MA, Rojas DP, Dell'Acqua V, Marvaso G, Bassi FD, Galimberti VE, Veronesi P, Miglietta E, Cattani F, Zurrida S, Bagnardi V, Viale G, Orecchia R, Jereczek-Fossa BA.

Radiother Oncol. 2019 Apr;133:68-76. doi: 10.1016/j.radonc.2018.12.030. Epub 2019 Jan 17.

PMID:
30935584
7.

Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review.

Esposito A, Viale G, Curigliano G.

JAMA Oncol. 2019 Mar 28. doi: 10.1001/jamaoncol.2019.0034. [Epub ahead of print]

PMID:
30920609
8.

Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.

Pece S, Disalvatore D, Tosoni D, Vecchi M, Confalonieri S, Bertalot G, Viale G, Colleoni M, Veronesi P, Galimberti V, Di Fiore PP.

EBioMedicine. 2019 Apr;42:352-362. doi: 10.1016/j.ebiom.2019.02.036. Epub 2019 Mar 5.

9.

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.

Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM.

Breast Cancer Res. 2019 Feb 22;21(1):30. doi: 10.1186/s13058-019-1118-z.

10.

Peptide vaccines in early breast cancer.

Criscitiello C, Viale G, Curigliano G.

Breast. 2019 Apr;44:128-134. doi: 10.1016/j.breast.2019.02.003. Epub 2019 Feb 7.

PMID:
30769238
11.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
12.

Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.

Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Gelber RD, Goldhirsch A.

Ann Oncol. 2019 Apr 1;30(4):653-655. doi: 10.1093/annonc/mdz034. No abstract available.

PMID:
30698647
13.

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients.

Fumagalli C, Catania C, Ranghiero A, Bosi C, Viale G, de Marinis F, Barberis M, Guerini-Rocco E.

J Clin Med. 2019 Jan 18;8(1). pii: E112. doi: 10.3390/jcm8010112.

14.

Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.

Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G.

Crit Rev Oncol Hematol. 2019 Jan;133:171-182. doi: 10.1016/j.critrevonc.2018.11.008. Epub 2018 Nov 26. Review.

PMID:
30661654
15.

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.

Dellapasqua S, Gray KP, Munzone E, Rubino D, Gianni L, Johansson H, Viale G, Ribi K, Bernhard J, Kammler R, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Colleoni M; International Breast Cancer Study Group.

J Clin Oncol. 2019 Feb 10;37(5):386-395. doi: 10.1200/JCO.18.00296. Epub 2018 Dec 27.

PMID:
30589600
16.

A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

Esposito A, Viale G, Criscitiello C, Curigliano G.

Expert Rev Clin Pharmacol. 2018 Nov 22. doi: 10.1080/17512433.2019.1552134. [Epub ahead of print]

PMID:
30466330
18.

OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.

Sciarra A, Schmidt S, Pellegrinelli A, Maggioni M, Dondossola D, Pasquier J, Cigala C, Tosi D, Halkic N, Bulfamante G, Viale G, Bosari S, Balabaud C, Bioulac-Sage P, Sempoux C.

Liver Int. 2019 Jan;39(1):158-167. doi: 10.1111/liv.13964. Epub 2018 Oct 8.

PMID:
30218633
19.

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01.

Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5.

PMID:
30196031
20.

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P.

Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31.

PMID:
30171067
21.

Sex as a predictor of response to cancer immunotherapy - Authors' reply.

Conforti F, Pala L, Bagnardi V, De Pas T, Marco M, Viale G, Gelber R, Goldhirsch A.

Lancet Oncol. 2018 Aug;19(8):e380-e381. doi: 10.1016/S1470-2045(18)30535-7. No abstract available.

PMID:
30102230
22.

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C; International Immuno-Oncology Biomarker Working Group.

Semin Cancer Biol. 2018 Oct;52(Pt 2):151-157. doi: 10.1016/j.semcancer.2018.07.001. Epub 2018 Jul 7. Review.

PMID:
29990622
23.

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.

Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, Sapino A.

Am J Surg Pathol. 2018 Sep;42(9):1190-1200. doi: 10.1097/PAS.0000000000001100.

24.

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.

Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, Hackl W, Thuerlimann B, Viale G, Colleoni M, Regan MM, Loi S.

JAMA Oncol. 2018 Oct 1;4(10):1335-1343. doi: 10.1001/jamaoncol.2018.1778.

25.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.

PMID:
29846122
26.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M.

Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30.

PMID:
29846104
27.

The Lymph Node and the Metastasis.

Tjan-Heijnen V, Viale G.

N Engl J Med. 2018 May 24;378(21):2045-2046. doi: 10.1056/NEJMcibr1803854. No abstract available.

PMID:
29791831
28.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A.

Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16.

PMID:
29778737
29.

Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis.

Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G.

Eur J Cancer. 2018 Jul;97:1-6. doi: 10.1016/j.ejca.2018.03.023. Epub 2018 May 17.

PMID:
29734046
30.

Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.

Grifantini R, Taranta M, Gherardini L, Naldi I, Parri M, Grandi A, Giannetti A, Tombelli S, Lucarini G, Ricotti L, Campagnoli S, De Camilli E, Pelosi G, Baldini F, Menciassi A, Viale G, Pileri P, Cinti C.

J Control Release. 2018 Jun 28;280:76-86. doi: 10.1016/j.jconrel.2018.04.052. Epub 2018 May 4.

PMID:
29733876
31.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

PMID:
29733336
32.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

33.

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M.

Breast Cancer Res Treat. 2018 Jul;170(2):351-360. doi: 10.1007/s10549-018-4767-1. Epub 2018 Mar 27.

PMID:
29589138
34.

The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.

Fumagalli C, Vacirca D, Rappa A, Passaro A, Guarize J, Rafaniello Raviele P, de Marinis F, Spaggiari L, Casadio C, Viale G, Barberis M, Guerini-Rocco E.

J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13.

PMID:
29535211
35.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

PMID:
29530933
36.

Targeting the microenvironment in solid tumors.

Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G.

Cancer Treat Rev. 2018 Apr;65:22-32. doi: 10.1016/j.ctrv.2018.02.004. Epub 2018 Feb 22. Review.

PMID:
29502037
37.

Immune Infiltration in Invasive Lobular Breast Cancer.

Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 Jul 1;110(7):768-776. doi: 10.1093/jnci/djx268.

38.

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.

Criscitiello C, Viale G, Curigliano G, Goldhirsch A.

Breast Cancer (Dove Med Press). 2018 Jan 30;10:23-29. doi: 10.2147/BCTT.S134641. eCollection 2018. Review. Erratum in: Breast Cancer (Dove Med Press). 2018 Mar 16;10 :51.

39.

Endomyocardial biopsy guided by intracardiac echocardiography as a key step in intracardiac mass diagnosis.

Zanobini M, Dello Russo A, Saccocci M, Conti S, De Camilli E, Vettor G, Catto V, Roberto M, Fiorentini C, Viale G, Tondo C, Casella M.

BMC Cardiovasc Disord. 2018 Jan 30;18(1):15. doi: 10.1186/s12872-018-0749-9.

40.

Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, Curigliano G.

Expert Opin Pharmacother. 2018 Feb;19(3):299-305. doi: 10.1080/14656566.2018.1429407. Epub 2018 Jan 22.

PMID:
29355400
41.

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.

Gianni L, Bisagni G, Colleoni M, Del Mastro L, Zamagni C, Mansutti M, Zambetti M, Frassoldati A, De Fato R, Valagussa P, Viale G.

Lancet Oncol. 2018 Feb;19(2):249-256. doi: 10.1016/S1470-2045(18)30001-9. Epub 2018 Jan 8.

PMID:
29326029
42.

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group.

Ann Oncol. 2018 Mar 1;29(3):646-653. doi: 10.1093/annonc/mdx773.

43.

TCTN2: a novel tumor marker with oncogenic properties.

Cano-Rodriguez D, Campagnoli S, Grandi A, Parri M, Camilli E, Song C, Jin B, Lacombe A, Pierleoni A, Bombaci M, Cordiglieri C, Ruiters MH, Viale G, Terracciano L, Sarmientos P, Abrignani S, Grandi G, Pileri P, Rots MG, Grifantini R.

Oncotarget. 2017 Aug 24;8(56):95256-95269. doi: 10.18632/oncotarget.20438. eCollection 2017 Nov 10.

44.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, De Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C.

Int J Oncol. 2018 Feb;52(2):424-432. doi: 10.3892/ijo.2017.4212. Epub 2017 Nov 27.

PMID:
29207087
45.

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee.

Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24.

46.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
47.

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.

J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20. Review.

PMID:
29053400
48.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

49.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Review.

50.

Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function.

Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, Ciraolo E, Franco I, Ala U, Annaratone L, Disalvatore D, Bertalot G, Viale G, Noatynska A, Compagno M, Sigismund S, Montemurro F, Thelen M, Fan F, Meraldi P, Marchiò C, Pece S, Sapino A, Chiarle R, Di Fiore PP, Hirsch E.

Cancer Cell. 2017 Oct 9;32(4):444-459.e7. doi: 10.1016/j.ccell.2017.09.002.

Supplemental Content

Support Center